Alnylam's Heart Drug Shows Promising Phase-3 Results, Boosting Stock

Vutrisiran demonstrates significant reduction in mortality and cardiovascular events in ATTR-CM patients, prompting regulatory filing plans.

Alnylam's stock surged over 31% following positive Phase-3 trial results for its heart drug, vutrisiran.
The drug showed a statistically significant reduction in deaths and recurrent cardiovascular events in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Vutrisiran also met all secondary endpoints, improving patients' ability to perform physical activities like walking.
Alnylam plans to seek regulatory approval, including a priority review from the FDA, later this year.
If approved, vutrisiran could become the new standard of care for ATTR-CM, potentially driving substantial growth for Alnylam.